1/39
Vocabulary flashcards covering cardiovascular pharmacology, clinical definitions, drug mechanisms, classifications, adverse effects, and guideline recommendations for hypertension and heart failure.
Positive Inotrope
An agent that increases the strength of cardiac muscle contraction.
Negative Inotrope
An agent that decreases the strength of cardiac muscle contraction.
Positive Chronotrope
An agent that increases the rate of cardiac contraction (heart rate).
Negative Chronotrope
An agent that decreases the rate of cardiac contraction (heart rate).
Cardiac Output (CO)
The volume of blood pumped by the heart each minute, calculated as stroke volume multiplied by heart rate (CO=SVĂHR).
Ejection Fraction (EF)
A measurement of the percentage of blood the left ventricle pumps out with each cardiac contraction.
Neprilysin
A neutral endopeptidase enzyme that degrades vasoactive substances, including natriuretic peptides, bradykinin, and adrenomedullin.
Natriuretic Peptides (ANP and BNP)
Endogenous peptides that increase endothelial vasodilation, promote renal natriuresis and diuresis, and inhibit myocardial fibrosis and cellular hypertrophy.
Normal Blood Pressure (2025 ACC/AHA)
A blood pressure classification defined as systolic blood pressure <120 mm Hg and diastolic blood pressure <80 mm Hg.
Elevated Blood Pressure (2025 ACC/AHA)
A blood pressure classification defined as systolic blood pressure of 120 to 129 mm Hg and diastolic blood pressure <80 mm Hg.
Stage 1 Hypertension (2025 ACC/AHA)
A blood pressure category defined as systolic blood pressure of 130 to 139 mm Hg or diastolic blood pressure of 80 to 89 mm Hg.
Stage 2 Hypertension (2025 ACC/AHA)
A blood pressure category defined as systolic blood pressure â„140 mm Hg or diastolic blood pressure â„90 mm Hg.
Hypertensive Emergency
Severely elevated blood pressure (typically systolic â„180 mm Hg and/or diastolic â„120 mm Hg) accompanied by acute, ongoing target organ damage, managed with parenteral agents in an intensive care setting.
Hypertensive Urgency
Severely elevated blood pressure (systolic â„180 mm Hg and/or diastolic â„110 mm Hg) in the absence of acute target organ damage, typically managed using oral antihypertensive medications over 24 to 48 hours.
Treatment Resistant Hypertension
Blood pressure that remains â„130/80 mm Hg despite concurrent therapy with three antihypertensive drug classes of complementary mechanisms (including a diuretic) at maximally tolerated doses, or blood pressure controlled only with four or more medications.
Pseudoresistant Hypertension
An apparent lack of blood pressure control caused by external confounders such as poor medication adherence, inaccurate measuring technique, white-coat effect, or suboptimal dosing regimens rather than true physiological resistance.
Angiotensin Converting Enzyme Inhibitors (ACE-I)
Antihypertensive agents that block the conversion of angiotensin I to angiotensin II and reduce bradykinin degradation, leading to vasodilation, reduced aldosterone release, and adverse effects including dry cough and angioedema.
Angiotensin II Receptor Blockers (ARBs)
Antihypertensive agents that selectively antagonize the angiotensin type 1 (AT1â) receptor to block angiotensin II vasoconstriction and aldosterone release without altering bradykinin breakdown.
Direct Renin Inhibitor (DRI)
A drug class represented by aliskiren that directly blocks renin activity, preventing the enzymatic conversion of angiotensinogen to angiotensin I.
Loop Diuretics
High-ceiling diuretics that compete with chloride at the Na+/K+/2Clâ cotransporter in the thick ascending limb of the loop of Henle, producing marked urinary loss of sodium, chloride, calcium, and magnesium.
Thiazide Diuretics
Sulfonamide-derived diuretics that inhibit the Na+/Clâ cotransporter in the distal convoluted tubule, producing hyperosmolar urine and uniquely enhancing calcium reabsorption.
Mineralocorticoid Receptor Antagonists (MRAs)
Potassium-sparing agents that antagonize aldosterone at intracellular mineralocorticoid receptors in the renal collecting duct, mitigating aldosterone-mediated fibrosis, remodeling, and potassium wasting.
Dihydropyridine Calcium Channel Blockers
A sub-class of calcium channel blockers (e.g., amlodipine, nifedipine) that preferentially bind L-type voltage-sensitive calcium channels in vascular smooth muscle to cause peripheral arteriolar dilation.
Non-Dihydropyridine Calcium Channel Blockers
Calcium channel blockers (verapamil and diltiazem) that act on both vascular smooth muscle and myocardium to exert prominent negative inotropic and negative chronotropic effects.
Cardioselective (ÎČ1â-Selective) Beta-Blockers
Second-generation beta-adrenergic blockers (e.g., metoprolol, atenolol, bisoprolol) that predominantly antagonize ÎČ1â receptors, lowering heart rate and myocardial contractility with minimal ÎČ2â-mediated bronchoconstriction.
Mixed Alpha/Beta-Adrenergic Blockers
Third-generation beta-blockers (carvedilol and labetalol) that combine non-selective beta-blockade with α1â-adrenergic receptor antagonism, lowering peripheral vascular resistance alongside heart rate.
Clevidipine (Cleviprex)
An intravenous-only, ultra-short-acting dihydropyridine calcium channel blocker formulated in a lipid emulsion, with onset within 2 to 4 minutes, contraindicated in patients with egg or soy allergies.
Esmolol
An intravenous-only, cardioselective ÎČ1â-blocker rapidly hydrolyzed by serum esterases, yielding an elimination half-life of approximately 8Â minutes.
Sodium Nitroprusside
A direct arterial and venous vasodilator that rapidly releases nitric oxide or stimulates guanylyl cyclase, carrying a potential risk of cyanide toxicity with prolonged or high-dose intravenous infusion.
Entresto (Sacubitril/Valsartan)
An angiotensin receptor-neprilysin inhibitor (ARNi) combination that increases vasoactive natriuretic peptides while blocking the AT1â receptor, used as foundational therapy in HFrEF.
36-Hour Washout Period
The mandatory time interval required between discontinuing an ACE inhibitor and administering the first dose of Entresto (sacubitril/valsartan) to prevent angioedema.
Finerenone (Kerendia)
A non-steroidal mineralocorticoid receptor antagonist indicated to reduce the risk of cardiovascular events, worsening heart failure, and CKD progression in type 2 diabetes and HF.
Ivabradine (Corlanor)
A selective inhibitor of the cardiac pacemaker hyperpolarization-activated cyclic nucleotide-gated (Ifâ) current in the SA node that reduces heart rate without altering contractility or blood pressure.
Digoxin (Lanoxin)
A digitalis glycoside that inhibits the myocardial Na+/K+-ATPase pump, raising intracellular sodium and calcium to increase contractile force while slowing conduction across the AV node.
Dobutamine (Dobutrex)
A ÎČ1â-adrenergic agonist that elevates intracellular cAMP and calcium influx, utilized as an intravenous inotrope for acute inpatient heart failure and cardiogenic shock.
Stage A Heart Failure
A heart failure classification describing patients at high risk for heart failure without current or prior symptoms, structural cardiac disease, or abnormal biomarkers.
Stage B Heart Failure (Pre-Heart Failure)
A heart failure classification encompassing patients without historical or current HF symptoms who demonstrate structural heart disease, elevated filling pressures, or elevated troponin/natriuretic peptides.
Stage C Heart Failure
A clinical stage characterized by current or previous symptomatic heart failure associated with underlying structural heart disease (such as reduced left ventricular ejection fraction).
Evidence-Based Beta-Blockers in HFrEF
The three beta-blockers clinically proven to decrease morbidity and mortality in symptomatic HFrEF: metoprolol succinate, carvedilol, and bisoprolol.
Foundational Guideline-Directed Medical Therapy (GDMT) for HFrEF
The quadruple medical regimen consisting of a RAAS inhibitor (preferably an ARNi), an evidence-based beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor.